News

MUHC Foundation Receives $2 million Donation to establish the MUHC’s Metabolic Centre of Excellence

MUHC Foundation Receives $2 million Donation to establish the MUHC’s Metabolic Centre of Excellence Marie-Hélène Laramée, Dr. Michael Tsoukas, Vince…

9 months ago

Benitec Biopharma Inc. Announces Pricing of $30 Million Common Stock Offering

HAYWARD, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene…

9 months ago

Prime Biome Reviews (Is It Legit And Safe Ingredients?) Can This Probiotic Really Transform Your Skin And Gut?

BOSTON, March 25, 2025 (GLOBE NEWSWIRE) -- The Prime Biome probiotic supplement that has been garnering attention in the health…

9 months ago

Burning Rock Reports Unaudited Fourth Quarter and Full Year 2024 Financial Results

GUANGZHOU, China, March 25, 2025 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a…

9 months ago

Cognition Therapeutics to Report Biomarker Results from Phase 2 SHINE Study in Mild-to-Moderate Alzheimer’s Disease in Podium Presentation at AD/PD 2025

Additional Analyses to be Presented at AD/PD Include Correlation of CSF Biomarkers with Cognitive Outcomes, and Pharmacodynamic Biomarkers of Target…

9 months ago

Enable Injections Announces Regulatory CE Mark Approval in Europe for enFuse Technology

CINCINNATI, March 25, 2025 (GLOBE NEWSWIRE) -- Enable Injections, Inc. (“Enable”), a healthcare innovation company developing and manufacturing the enFuse® wearable drug…

9 months ago

Quoin Pharmaceuticals Files U.S. Patent Application for Novel Topical Formulations to Treat Netherton Syndrome and Other Skin Diseases

Target Indications Also Include Peeling Skin Syndrome, SAM Syndrome, Palmoplantar Keratoderma and Severe Atopic DermatitisThird Quoin Patent Application for Netherton…

9 months ago

Relmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma, Ltd.

NDV-01 is a novel, sustained-release, intravesical gemcitabine/docetaxel, ready-for-use product candidate for the treatment of non-muscle invasive bladder cancer (NMIBC, U.S.…

9 months ago

Traws Pharma’s COVID-19 Candidate, Ratutrelvir, Presented at ICAR

Preclinical and Phase 1 data suggest that ratutrelvir can be used without ritonavir and may reduce the likelihood of COVID…

9 months ago

CorMedix Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

‒ Q4 2024 Net Revenue of $31.2mm; 2024 Net Revenue of $43.5mm ‒ ‒ Q4 Net Income of $13.5mm and…

9 months ago